HPS Pharmacies wish to advise that multiple sponsors are experiencing a supply interruption for pramipexole 0.125mg and 0.25mg tablets as follows:
| Product | ARTG | Expected return date |
| APO-Pramipexole 0.125mg | 227666 | Late January 2026 |
| Sifrol 0.125mg | 67238 | Mid-December 2025 |
| Simipex 0.125mg | 172017 | Late February 2026 |
| Simpral 0.125mg | 173139 | Early January 2026 |
| APO-Pramipexole 0.25mg | 227667 | Late January 2026 |
| Sifrol 0.25mg | 66484 | Mid-December 2025 |
| Simipex 0.25mg | 172018 | Late January 2026 |
| Simpral 0.25mg | 173138 | Late-December 2025 |
An internationally registered alternative of pramipexole 0.125mg and 0.25mg tablets has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates